scholarly article | Q13442814 |
P50 | author | Emanuele Montomoli | Q43110625 |
Paul Anantharajah Tambyah | Q47499195 | ||
Otfried Kistner | Q93004381 | ||
Sandor Fritsch | Q104744986 | ||
Hartmut J Ehrlich | Q104745018 | ||
P Noel Barrett | Q104745030 | ||
P2093 | author name string | Markus Müller | |
Eva Maria Pöllabauer | |||
Maikel V W van der Velden | |||
Alexandra Löw-Baselli | |||
Borislava G Pavlova | |||
Friedrich Maritsch | |||
Greg Berezuk | |||
Helen M L Oh | |||
Markus Zeitlinger | |||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1113-1118 | |
P577 | publication date | 2009-10-01 | |
P1433 | published in | Journal of Infectious Diseases | Q4051141 |
P1476 | title | A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. | |
P478 | volume | 200 |
Q30418715 | A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination |
Q30224624 | A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate |
Q30359896 | A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. |
Q30419799 | A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory |
Q36086664 | A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses |
Q30386068 | A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. |
Q38056159 | A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use. |
Q30224538 | A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®]. |
Q30224497 | Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. |
Q28084739 | Cell culture-based influenza vaccines: A necessary and indispensable investment for the future |
Q30419591 | Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production |
Q44278166 | Clinical development of a Vero cell culture-derived seasonal influenza vaccine |
Q30382947 | Continuous cell lines as a production system for influenza vaccines. |
Q57158300 | Correlates of Protection Against Influenza |
Q83880292 | Differences in the priming effect of various clades/subclades of inactivated H5N1 vaccine for booster injection with heterologous clades of vaccine strains |
Q30226730 | Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial |
Q30409570 | Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion |
Q30353991 | Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. |
Q30395944 | Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. |
Q27000896 | H5N1 vaccines in humans |
Q28741304 | H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model |
Q30424002 | Immunogenic and protective properties of the first Kazakhstan vaccine against pandemic influenza A (H1N1) pdm09 in ferrets. |
Q30372141 | Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs. |
Q42178340 | Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial |
Q30362811 | Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. |
Q30367695 | Influenza vaccines: a moving interdisciplinary field. |
Q30402018 | MF59 adjuvant: the best insurance against influenza strain diversity |
Q30411859 | New technologies for influenza vaccines |
Q30383323 | On the press coverage on the Austrian allocation of vaccine against the pandemic influenza A/H1N1 |
Q30368247 | Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults. |
Q30414998 | Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. |
Q30420569 | Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine |
Q30381595 | Refining the approach to vaccines against influenza A viruses with pandemic potential. |
Q44197848 | Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013. |
Q37918307 | Return of inactivated whole-virus vaccine for superior efficacy |
Q30210481 | Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients |
Q34073541 | Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine |
Q37919896 | The future of cell culture-based influenza vaccine production |
Q30429058 | Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development |
Search more.